Those results compare to the high bar set by two authorized
vaccines from Pfizer Inc/BioNTech SE and Moderna Inc, which were
around 95% effective in preventing symptomatic illness in
pivotal trials when given in two doses.
Those trials, however, were conducted mainly in the United
States and before the broad spread of new variants now under the
spotlight.
At 8:06 a.m. ET, Dow e-minis were down 342 points, or 1.12%, S&P
500 e-minis were down 40.25 points, or 1.07%, and Nasdaq 100
e-minis were down 150 points, or 1.14%.
(Reporting by Sagarika Jaisinghani in Bengaluru; Editing by
Shounak Dasgupta)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|